Valvular Heart Disease Medical Services in China

Valvular heart disease encompasses structural or functional abnormalities of one or more cardiac valves—mitral, aortic, tricuspid, or pulmonary—leading to stenosis (narrowing), regurgitation (insufficiency), or prolapse. Common etiologies include degenerative changes, rheumatic fever, infective endocarditis, congenital defects, and age-related calcification. Symptoms may range from asymptomatic murmurs to dyspnea, fatigue, orthopnea, palpitations, syncope, or acute decompensated heart failure. Diagnosis relies on comprehensive echocardiography (TTE/TEE), cardiac MRI, and hemodynamic assessment via right-heart catheterization when indicated. Management spans pharmacologic therapy for symptom control to definitive interventions—including transcatheter valve replacement (TAVR, TMVR), minimally invasive surgical repair/replacement, or conventional open-heart surgery—tailored to valve anatomy, patient risk profile, and functional status.

China offers distinct advantages in valvular heart disease care: its leading cardiovascular centers—such as Fu Wai Hospital and Shanghai Ruijin Hospital—rank among the world’s top 10 for procedural volume and outcomes, with extensive experience in complex redo surgeries and high-risk TAVR cases. Advanced imaging integration, robotic-assisted techniques, and domestically developed transcatheter devices enhance precision and safety. Clinical data demonstrate 30-day mortality rates comparable to Western benchmarks, with robust 5-year survival post-surgery. Crucially, costs for valve interventions in China are typically 40–60% lower than in the US or UK, without compromising quality—thanks to streamlined regulatory pathways and efficient healthcare delivery.

As a dedicated medical tourism agency, we facilitate seamless access for international patients: vetting JCI-accredited hospitals, coordinating pre-arrival diagnostics, arranging bilingual clinical consultations, ensuring transparent all-inclusive pricing, and providing end-to-end support—from visa assistance and accommodation to postoperative follow-up coordination.

Treatment Options & Itemized Cost Breakdown: Valvular Heart Disease (Cardiology Department)

Non-Surgical / Conservative Management

*Indicated for asymptomatic mild-moderate disease, contraindications to surgery, or preoperative stabilization.*

• •Medications (Monthly)

- Beta-blockers (e.g., metoprolol): $6–$10 - Anticoagulants (warfarin/DOACs): $25–$65 (apixaban rivaroxaban higher tier) - ACEi/ARBs (for LV dysfunction): $10–$18

• •Monitoring & Diagnostics (Per Episode)

- ECG + Holter monitoring: $20–$35 - BNP/NT-proBNP assay: $18–$28 - Renal function + INR panel: $12–$22

Surgical & Interventional Procedures

*Eligibility: Symptomatic moderate-severe stenosis/regurgitation, LVEF ≤50%, progressive ventricular dilation, or pulmonary hypertension.*

• •Transcatheter Aortic Valve Implantation (TAVI)

- Procedure (valve + cath lab + anesthesia): $18,500–$26,200 - Hospital stay (5–7 days): $1,100–$1,600

• •Surgical Aortic/ Mitral Valve Replacement (SAVR)

- Procedure (mechanical/bioprosthetic valve + CPB): $12,800–$19,400 - Hospital stay (7–10 days): $1,400–$2,100

• •Mitral Valve Repair (MVR)

- Procedure (annuloplasty, chordal reconstruction): $14,200–$20,600 - Hospital stay: $1,400–$2,100

Special/Complex Condition Management

• •Reoperative Valve Surgery (prior sternotomy, endocarditis, prosthetic failure): $17,500–$24,800 (includes extended CPB, complex tissue reconstruction)
• •Combined CABG + Valve Surgery: $21,000–$29,500
• •Endocarditis-directed therapy (IV antibiotics × 4–6 weeks + surgical debridement): $8,200–$13,600 (includes ICU days, blood cultures, valve culture)

Quick Selection Guide

• •Age <65, no comorbidities, severe AS/MR: Surgical repair/replacement — optimal durability, cost-effective long-term ($14,200–$19,400)
• •Age ≥75, frailty/COPD/renal impairment: TAVI — lower perioperative risk, faster recovery ($19,600–$27,800)
• •Asymptomatic moderate disease + tight budget: Conservative management + biannual echo ($120–$200/year)
• •Active infective endocarditis + vegetation >10 mm: Urgent surgical debridement + valve replacement — mortality reduction outweighs cost ($17,500–$24,800)
• •Severe MR with preserved EF but high surgical risk: Transcatheter edge-to-edge repair (MitraClip) — available at select 3A centers ($22,000–$28,500)